Ionis Pharmaceuticals Announces Key Upcoming Investor Events
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has recently announced its participation in several notable investor conferences. This engaging opportunity is set to showcase the company's innovative work and advancements in RNA-targeted medicines.
Investor Conference Details
Management from Ionis will be taking part in fireside chats at the following investor gatherings:
Guggenheim's Inaugural Healthcare Conference
Scheduled for mid-November, this conference marks a significant event for many stakeholders in the healthcare sector.
UBS Global Healthcare Conference
Also taking place on the same day as the Guggenheim's event, this conference reinforces Ionis' commitment to connecting with the investment community.
Stifel 2024 Healthcare Conference
Later in November, Ionis will be featured at this influential gathering, further highlighting its position in the healthcare landscape.
Jefferies London Healthcare Conference
This event is particularly important as it allows Ionis to connect with European investors and stakeholders.
Citi's 2024 Global Healthcare Conference
In early December, Ionis will participate in this global conference, enhancing its visibility in the healthcare market.
Piper Sandler 36th Annual Healthcare Conference
Wrapping up the conference schedule for the year, this event is anticipated to bring great exposure for Ionis and its innovative therapies.
Webcast Accessibility
Investors and interested parties can access live webcasts of the presentations through the Ionis website. This feature allows broader engagement and ensures that stakeholders can stay informed about the latest developments.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals has a rich history of over thirty years inventing medicines that offer better futures for individuals facing serious diseases. With a portfolio that includes five marketed products and an impressive pipeline focused on neurology and cardiology, Ionis is at the forefront of RNA-targeted therapies. The company’s dedication to innovation extends beyond RNA therapies as it also explores cutting-edge approaches to gene editing. This deep-rooted understanding of disease biology, coupled with top-tier technology, drives Ionis Pharmaceuticals forward in delivering life-enhancing solutions for patients.
Staying Connected with Ionis
If you want to keep up with Ionis Pharmaceuticals, you can easily visit their official website and engage on social media platforms to see how they are progressing in their mission.
Frequently Asked Questions
What conferences will Ionis participate in?
Ionis will participate in events hosted by Guggenheim, UBS, Stifel, Jefferies, Citi, and Piper Sandler.
How can investors access the presentations?
Investors can access live webcasts of the presentations on the Ionis website.
What is the focus of Ionis Pharmaceuticals?
Ionis focuses on developing RNA-targeted medicines and has significant expertise in neurology and cardiology.
How long has Ionis been in operation?
Ionis Pharmaceuticals has been innovating in medicine for over 30 years.
Who can I contact for investor relations?
D. Wade Walke, Ph.D., is the investor contact at Ionis Pharmaceuticals.